WORX
SCWorx Corp
-25.75%
$0.44 - $0.33
Feb 7th 2023 - Mar 21st 2023
Dec, 5, 2022
The new product offering enables hospitals of all ... See more
Dec, 5, 2022
New products and a chart with mega upside. 🚀
AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Jan, 13, 2023
They have a great product treating cancer with imm... See more
Jan, 6, 2023
look into Adamis Pharma, no more speculation, now ... See more
AUPH
Aurinia Pharmaceuticals Inc
3.07%
$8.48 - $8.74
Feb 8th 2023 - Mar 22nd 2023
Mar, 22, 2023
For a one product company, we sure have a lot of p... See more
Mar, 19, 2023
Should be very easy to beat EOY guidance for product revenue.
Dec, 5, 2022
The new product offering enables hospitals of all sizes to quickly and easily benefit from the SCWorx data platform.
Dec, 5, 2022
New products and a chart with mega upside. 🚀
Dec, 5, 2022
$WORX Business booming with more clients new products and a chart bottomed ready to go 🚨🚨🚨❗️💎 a gem
Dec, 5, 2022
$WORX is consistent with good PR, new contracts, new products and stock purchase deals with institutional investors!
Jan, 13, 2023
They have a great product treating cancer with immunotherapy, peer reviewed journal
Jan, 6, 2023
look into Adamis Pharma, no more speculation, now it's real, two FDA approved meds, two major products, top of the line in comparison of their rivals, for cheaper price, AND WITH NO MUCH COMPETITION!
Dec, 14, 2022
2023 is going to be very positive for patients of our products and shareholders alike
Dec, 6, 2022
Their product works (see the mad Pole Piotr’s graphs 😵💫) Multi year holds, the bodadem.
Dec, 5, 2022
We have great data out of a superior product,
Oct, 18, 2022
They have good products and a solid future.
Mar, 22, 2023
For a one product company, we sure have a lot of people feeding off of it; think management, the board, the fantastic sales team.
Mar, 19, 2023
Should be very easy to beat EOY guidance for product revenue.
Feb, 14, 2023
The product is good.
Jan, 26, 2023
First product to market usually secures the top spot for a long time, and Benlysta has delivered well for GSK.
Nov, 21, 2022
$AUPH Another 1 trick pony ZM getting killed and they have a better product.
Nov, 11, 2022
Real product,
Oct, 20, 2022
3 other approved products, all growing revenue.
Oct, 13, 2022
$AUPH looking at RLMD, we can be glad we have an approved product here that works well for its patients.